Recent evidence indicates that long-term visit-to-visit blood pressure variability (BPV) may be an independent cardiovascular risk predictor. The implication of this variability in hypertension clinical practice is unclear. BPV as average real variability (ARV) was calculated in 14 522 treated patients with hypertension in 4 time frames: year 1 (Y 1 ), years 2 to 5 (Y 2-5 ), years 5 to 10 (Y 5-10 ), and years >10 (Y 10+ ) from first clinic visit. Cox proportional hazards models for cause-specific mortality were used in each time frame separately for long-term BPV, across time frames based on ultra long-term BPV, and within each time frame stratified by mean BP. ARV in systolic blood pressure (SBP), termed ARV SBP , was higher in Y 1 (21.3±11.9 mm Hg) in contrast to Y 2-5 (17.7±9.9 mm Hg), Y 5-10 (17.4±9.6 mm Hg), and Y 10+ (16.8±8.5 mm Hg). In all time frames, ARV SBP was higher in women (P<0.01) and in older age (P<0.001), chronic kidney disease (P<0.01), and prevalent cardiovascular disease (P<0.01). Higher long-term and ultra long-term BPV values were associated with increased mortality (all-cause, cardiovascular, and noncardiovascular mortality; P for trend, <0.001). This relationship was also evident in subgroups with mean SBP<140 mm Hg in all time frames. Monitoring BPV in clinical practice may facilitate risk reduction strategies by identifying treated hypertensive individuals at high risk, especially those with BP within the normal range. (Hypertension. 2013;62:698-705.) • Online Data Supplement surviving until the end of the test time frame. All models were adjusted for mean time-weighted SBP and DBP (SBP tw and DBP tw ), and baseline cardiovascular risk factors, including age, sex, smoking, alcohol consumption, body mass index, total cholesterol, prevalent cardiovascular disease (CVD), and estimated glomerular filtration rate. Furthermore, in analyses of Y 1 and Y 2-5 , a variable on year of first visit strata (epochs) was included to adjust the secular trend in mortality and this was divided into 5 categories (first visit 1976 or earlier, between years 1977 and 1987, between 1988 and 1997, between 1998 and 2004, and 2005 and later). Log-minus-log plots were analyzed for any suggestion of deviation from the proportional hazards assumption. 21
I t is well recognized that blood pressure (BP) is inherently variable in an individual. This variability (BPV) manifests as the diurnal BP rhythm with nocturnal dipping, pseudoperiodic variability (obtained from spectral analysis of beat-tobeat recordings), and variability between BP measurements separated by minutes, hours, weeks, months, or years. The intraindividual fluctuation of BP is physiologically attributed to baroreflex, autonomic function, and response to challenge (demands for greater tissue perfusion in response to emotion, mood, stress, wakefulness, ambient temperature, and physical activity). 1, 2 Several streams of evidence suggest that BPV is associated with increased cardiovascular risk independent of BP. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] There is convincing evidence that shortterm BPV (obtained from multiple BP measurements during a 24-hour period) predicts end-organ damage and cardiovascular events. [5] [6] [7] [8] However, the question of whether long-term visit-to-visit BPV (which potentially reflects a more diverse set of influences than short-term 24-hour BPV) also independently predicts clinical outcomes has received more attention recently. [9] [10] [11] [12] 16 One of the original studies in this area identified an association between visit-to-visit BPV and an increased risk of coronary events. 4 Post hoc analyses of large randomized control trials have found associations between high visitto-visit BPV and increased stroke incidence in a population of subjects at increased risk of vascular events. 11 Moreover, further analyses of treated hypertensive populations in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)-BP-Lowering Arm (BPLA) found that increased systolic BPV between clinic visits was associated with stroke and coronary events. 13 The general population National Health and Nutrition Examination Survey (NHANES) study demonstrated a 50% increased risk in subjects in the higher tertiles of BPV compared with that in subjects in the lowest tertile. 10 Interestingly, long-term intraindividual BPV has little correlation with concomitant short-term 24-hour BPV (correlation coefficient, <0·2), suggesting that they may relate to different underlying mechanisms. 17 All these imply that long-term BPV is a marker of risk that is currently not captured by the office-based and ambulatory BP measurements routinely used in clinical practice. If long-term BPV is indeed truly independent of longterm average BP, then monitoring BPV in clinical practice will have an impact on hypertension practice. In real-life practice, BP tends to be measured at varying intervals and treatment titration and adherence differ among patients; consequently, in this setting, the association between BPV and risk and its use in clinical practice is unclear. We studied the Glasgow Blood Pressure Clinic population followed for ≤35 years to determine the associations and characteristics of BPV in relation to different follow-up time frames and long-term mortality.
Methods

Study Population
We studied all patients attending the Glasgow Blood Pressure Clinic, a service that has provided secondary and tertiary care to patients with hypertensive in the West of Scotland since 1968. Data from 16 011 attendees are stored in the clinic's database. All participants are treated patients with hypertension. Mortality outcomes were derived using record linkage with the General Register Office for Scotland. Outcome classification details are provided in the onlineonly Data Supplement. Use of the anonymized database for analyses is approved by the West of Scotland research ethics service of the National Health Service.
BP Measurements
The Glasgow Blood Pressure Clinic uses specialist hypertension nurses who are experienced and highly trained in BP measurement. The procedure required subjects to rest for 5 minutes in a seated position before BP was manually measured using standard sphygmomanometers, and Korotkoff sounds (phase V) were used for estimating diastolic BP (DBP). Three BP measurements were performed, 1 minute apart, and the mean of the second and third measurements was recorded. Patients attending the clinic were advised to take their regular medications as usual. Each patient attended the same clinic; therefore, at each visit, their BP measurement would occur in the same 3-hour time window in either the morning or the afternoon sessions. Consumption of food and drink and the level of physical exertion before each clinic appointment could not be controlled. Drug substitution, addition, and dose adjustment occurred during follow-up and in accordance with clinical guidelines. Prescribed medications were cross-checked with patients at each clinic visit, and they were advised to comply with their treatment at all times. A more accurate measure of the time between drug consumption and BP measurements was unavailable. Information on specific medications, their doses, and formal concordance testing was unavailable.
BP Trait Definitions
BPV was calculated and analyzed in different time frames rather than during the entire follow-up period, primarily because the determination of BPV depends on multiple BP measurements over a period of time, and in real-life practice, it is impossible to maintain the same frequency of BP measurements over long time periods. Moreover, we hypothesize that the interval between BP clinic visits increases over time as BP gets better controlled, leading to less-frequently recorded clinic BP values. Furthermore, other factors that may affect BPV, such as age and renal function, vary over time, and further heterogeneity introduced by antihypertensive drug titration/substitution/ addition will be greater in the earlier stages of follow-up to get BP on target, in contrast with later periods of follow-up when patients are established on treatment. Therefore, we hypothesize that BPV will be more informative and reliable when calculated over shorter periods in real-world data.
We defined 2 types of BPV in this study: long-term visit-to-visit BPV calculated over a time period of 1 to 5 years; and ultra longterm variability (BPV ul ) as visit-to-visit BPV over a period >5 years. The definitions of these time periods were derived from a review of the BP clinic visits and BP measurement data available in our database. Long-term BPV was measured within each of 4 time frames for analysis as periods of follow-up from the first visit to clinic; year 1 (Y 1 ), years 2 to 5 (Y 2-5 ), years 5 to 10 (Y 5-10 ), and years >10 (Y 10+ ). To be included in each time frame for analysis, subjects were required to have a minimum of 3 BP readings ≥30 days apart. Other exclusion criteria were extremes of age (<20 and >80 years) and body mass index (<15 and >50 kg/m 2 ). A detailed flowchart of the study is presented in Figure S1 in the online-only Data Supplement.
For each time frame, we calculated average real variability (ARV SBP , ARV DBP ), coefficient of variation (CoeffV SBP , CoeffV DBP ), and SD SBP , SD DBP for both systolic BP (SBP) and DBP as metrics of BPV. The estimates of variability calculated using these approaches have been shown to be only partly correlated and may have different primary determinants. 11,18 ARV=
absolute difference between successive BP measurements, and in contrast with CoeffV, it takes the order of the BP measurements into account while quantifying variability between adjacent readings. An advantage of ARV is that it is less affected by trends. 19, 20 We calculated the mean BP for each time frame using a time-weighted average of all BP measurements (SBP tw , DBP tw ) during the interval to remove any upward bias of the mean BP caused by more-frequent appointments when BP was uncontrolled. The formulae used for calculating these metrics are presented in the online-only Data Supplement. Finally, quartiles of ARV were determined for each time period. In addition to the above analyses, we also studied sustained BPV over longer time periods (ultra long-term [BPV ul ]) spanning 5 and 9 years. To determine the BPV ul status of each individual and to minimize the biases introduced by the differing frequencies of BP measurements available during very long-term follow-up of patients, we used the BPV calculated during sequential time frames. For this, we divided patients into 4 groups depending on the longitudinal pattern of change in BPV over time. BPV change was measured >5 years between time periods Y 1 and Y 2-5 and >9 years between time periods Y 2-5 and Y [5] [6] [7] [8] [9] [10] . Using a median ARV SBP of 17 and comparing Y 1 and Y 2-5 , we classified subjects into those who had a sustained high (highhigh) or low (low-low) BPV SBP and subjects whose BPV SBP was not sustained over time (low-high or high-low). We used ARV SBP =17 as a cutoff because it facilitated the division of our cohort into 4 groups with approximately equal sample sizes. The same categorization procedure was undertaken for DBP using a threshold of ARV DBP =9, again comparing Y 1 and Y 2-5 . Similar analyses were repeated comparing Y 2-5 with Y 5-10.
Statistical Analysis
Summary statistics of baseline participant characteristics were calculated and groups were compared statistically by ANOVA or independent t tests for continuous variables and by χ 2 tests for categorical variables. Categorical variables are shown as counts and percentages and continuous variables are shown as means (±SD).
Congruence of BPV among time frames and the correlations between BPV and average BP are detailed in the online-only Data Supplement.
Univariate survival analysis was performed using Kaplan-Meier survival plots and log rank tests. Cox proportional hazards models were used to determine the multivariate adjusted risk of all-cause, ischemic heart disease, stroke, cardiovascular, or noncardiovascular mortality for each quartile of ARV BP , with the lowest quartile serving as the referent. Separate analyses were performed for SBP and DBP, and for each follow-up time frame: Y 1 , Y 2-5 , Y 5-10 , and Y 10+ , and the BPV ul groups. For survival analyses performed on each successive time frame, deaths occurring up to the end of the test time frame were excluded. Survival in each successive time frame was thus conditional on the individual by guest on October 18, 2017 http://hyper.ahajournals.org/
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Results
Sample Baseline Demographic Characteristics
At baseline, after exclusions based on age and body mass index, 14 522 participants had basic demographic information recorded. Of these, 6952 (47.9%) were men and 6094 (42.0%) were smokers. The median survival time was 29.32 years. The baseline characteristics, stratified by sex, are presented in Table 1 . The numbers of subjects available for BPV and BPV ul analyses were as follows: 7136 (Y 1 ), 5715 (Y 2-5 ), 2685(Y 5-10 ), 1292 (Y 10+ ), 4491 individuals (Y 1 and Y 2-5 ), 2514 (Y 2-5 and Y 5-10 ), and 1620 (Y 1 , Y 2-5 , and Y 5-10 ; Figure S1 ). The intervisit intervals of BP measurements used in each time frame were 77.9±37.1, 157.5±111.9, and 204.1±193 days for Y 1 , Y 2-5 , and Y 5-10 , respectively, and the numbers of BP measurements contributing to BPV calculation in each time frame were Y 1 : 3.6±0.8 (median, 4; interquartile range, 3-6), Y 2-5 : 7.8±3.2 (7; 4-10), and Y 5-10 : 7.9±3.7 (6; 4-10) . The average number of drugs in each time frame increased from Y 1 (2.08±0.99) to Y 2-5 (2.25±1.069) to Y 5-10 (2.49±1.169). BPV was higher in Y 1 than during later time frames (Results in the online-only Data Supplement; Table S1 ).
Overall, there was poor agreement between all measures of BPV among the different time frames (intraclass correlation, <0·32; Results in the online-only Data Supplement; Tables S2  and S3 ). Similarly, within each time frame, there were only moderate correlations (r<0·5) between measures of BPV and BP tw (Results in the online-only Data Supplement; Table S4 ). However, among time frames, 60% of subjects were concordant and 40% discordant for BPV levels between consecutive time frames (see Discussion; Tables S5 and S11 ). The latter group is responsible for the poor overall agreement among time frames.
BPV and Baseline Characteristics
ARV SBP was consistently higher during all follow-up time frames in women (P<0.01) and in participants of older age (P<0.001), with baseline chronic kidney disease (P<0.01), and baseline-prevalent CVD (P<0.05). High baseline SBP (>160 versus <160 mm Hg) and high baseline mean SBP tw (>160 versus <160 mm Hg) were both associated with greater ARV SBP (P<0.001; Results in the online-only Data Supplement; Tables S1 and S6A). ARV DBP showed similar associations (Results in the online-only Data Supplement; Table S6B ).
BPV and Mortality in Different Follow-Up Time Frames
For survival analysis performed for each successive time frame, deaths occurring up to the end of the test time frame were excluded. Survival in each successive time frame was thus conditional on the individual surviving until the end of the test time frame. The total times at risk for analyses were 101 901, 63 503, 24 001, and 109 88 person-years of follow-up at Y 1 , Y 2-5 , Y 5-10 and Y 10+ , respectively (Tables S7A and S7B for SBP and DBP, respectively). For all mortality outcomes, the number of events increased with increasing BPV. The results of Cox proportional hazards models for ARV SBP and ARV DBP are presented in Figure 1 and Table S8 . Increasing quartiles of ARV SBP in Y 1 were associated with increased risk of all-cause (P for trend, <0.001), cardiovascular (P for trend, <0.001), and ischemic heart disease mortality (P for trend, <0.001). The results were consistent during most, but not all, follow-up time frames. The results for ARV DBP were not as consistent as those for ARV SBP , with increasing quartiles of ARV DBP in Y 1 associated with increased risk of all-cause (P for trend, <0.01) and cardiovascular mortality (P for trend, <0.05) only. Stroke mortality did not show any association with BPV. Non-CVD mortality was consistently elevated in higher ARV SBP quartiles in all follow-up time points up to year 10.
Results of analyses of alternative measures of BPV, coefficient of variation and SD, are similar but less consistent than the results of ARV for SBP and DBP. The results are presented Tables S9 and S10.
BPV and Mortality at Different Mean BP Levels
To separate the effects of BPV and long-term average BP, analyses using Cox proportional hazards models of ARV SBP were performed in groups stratified by mean SBP tw into <140, 140 to 160, and >160 mm Hg categories (Table 2) . Again, Cox models were adjusted for mean time-weighted SBP (SBP tw ), DBP (DBP tw ), and baseline cardiovascular risk factors, including age, sex, smoking, alcohol consumption, body mass index, total cholesterol, prevalent CVD, estimated glomerular filtration rate, and epochs. Within each strata of SBP tw , the highest quartile of BPV was associated with a >40% increased risk of all-cause mortality compared with the lowest quartile in Y 1 and Y 2-5 and for cardiovascular and noncardiovascular mortalities ( Table 2) . 
Effect of Ultra Long-Term Sustained BPV (BPV ul ) and Mortality
BPV ul during the first 5 years was defined by comparing BPV in Y 1 with that in Y 2-5 and that for 9 years, by comparing Y 2-5 with Y 5-10 (Tables S5 and S11). The association of BPV ul with mortality was essentially similar to that of long-term BPV. Figure 2 shows Kaplan-Meir plots for all-cause mortality and CVD mortality, and the multivariate-adjusted hazard ratios for all cause-specific mortalities are presented in Table S12 .
Discussion
In this study, we show, using real-world clinical BP data in a large cohort, that both long-term BPV SBP and BPV DBP calculated for different long-term sequential time frames (duration The association between BPV and mortality is clear for all-cause, cardiovascular, and noncardiovascular mortality. However, we do not show an association with stroke mortality. Retrospective analyses of the INternational VErapamil SR Trandolapril STudy (INVEST) and ASCOT studies have shown consistent association between higher BPV and incident stroke 9, 18 ; however, we analyzed stroke mortality rather than incident stroke and show no association with BPV. We do not have data on incident stroke and hence we are unable to explain this finding.
There is only modest correlation between BPV and longterm average BP, and we show that even with well-controlled mean SBP<140, there is a linear increase in mortality with increasing BPV. The linear relationship between BPV and mortality is maintained in all time frames, including Y 1 , despite higher mean BPV in Y 1 . Our data for Y 1 can be considered a quasi-intervention study, where variability is inflated primarily through physician-induced drug titration. BPV values in later time frames of follow-up are lower and more probably reflect basal variability on an established treatment regime with possibly lower effect from drug adherence issues. All these indicate that BPV captures a risk trait that is unrelated to BP and could reflect specifically a response to external challenges. Like us, other reports have shown that BPV across different time frames is poorly reproducible. 12, 22 We also show that despite low overall reproducibility of BPV across sequential time frames, those individuals who show sustained high or low BPV ul over longer time frames of 6 to 9 years have higher and lower mortality, respectively, independent of long-term average BP. The consistent BPV ul sustained over long time periods occurs irrespective of the length of time for which BPV was calculated; we compared BPV calculated for 1-and 4-year periods and, in another analysis, for 4-and 5-year periods. Those subjects with unstable BPV status in sequential time frames are mainly those with BPV closer to the threshold, where even minor changes might have led to a change in the category. This would be in line with the intermediate risk of mortality in this group and is consistent with our other results that there is a graded increase in risk with increasing BPV over longterm or ultra long-term periods.
We speculate that BPV calculated over much shorter time frames, for example for 24 hours, may behave in a similar manner based on the recent observation of little correlation between visit-to-visit intraindividual BPV and concomitant short-term 24-hour BPV. 17 However, this analysis is beyond the scope of our data set.
We calculated and analyzed BPVs in different time frames rather than the entire follow-up period for the following reasons: the determination of BPV depends on multiple BP measurements over a period of time, and in real-life practice, it is impossible to maintain the same frequency of BP measurements over long time periods; other factors that may affect BPV across time, such as age, drug treatment, renal function, vary over time. Although this has helped us dissect the association between BPV and outcomes, implementing BPV assessment in clinical practice will need to address this important practical issue of defining the best method of obtaining a reliable index of BPV. It may be argued that differences in risk seen in the sustained low BPV and high BPV groups may simply reflect the differences in the burden of comorbidities, despite statistically adjusting for them in the models. Although both BP and BPV increase with age, we show that BPV remains an independent predictor of risk at all strata of mean BP. More importantly, the survival analyses were conditional on the individual surviving for 5 and 9 years in the Y 1 to Y 2-5 and the Y 2-5 to Y 10 groups, respectively, thus minimizing reverse causation confounding the results in the 4-group analyses.
To date, in published literature, no association has been shown between visit-to-visit DBP variability and mortality. ASCOT-BPLA showed an association with stroke risk in the highest deciles of DBP BPV. 4, 10, 11, 23 In this study, we show DBP BPV is associated with higher mortality risk in Y 1 , Y 5-10 , and Y 10+ . Y 2-5 did not show any association between BPV and mortality. The association with noncardiovascular mortality was much stronger in the Y 10+ group for DBP BPV than for SBP BPV. The reason for this is unclear. Our study offers new insight into the prognostic role of DBP variability, presenting significant associations with all-cause, cardiovascular, and noncardiovascular mortality.
In our study, ARV is a better and more consistent predictor of outcomes than SD or CoeffV across different time frames. This is not surprising as BPV from ABPM data have shown that ARV was a better predictor of outcomes than SD or CoeffV. 19, 24, 25 It is also probable that ARV, CoeffV, and SD may reflect different primary determinants as they are only partly correlated. 11, 18 ARV measures changes between consecutive BP readings, whereas SD or CoeffV give more weight to extreme values and are, therefore, more sensitive to instability in BP related to specific stressors (posture, emotional stress, and pain). 20 ARV is also a more specific predictor of 24-hour BPV than SD because subjects with different 24-hour ABPM profiles may have similar SDs but different ARVs. 19, 24 Our study is not without limitations; the observational nature lends itself to bias, all subject data are derived from a single-center hypertensive clinic cohort, lack of fixed-intervisit intervals between BP readings, and variable number of BP readings available in each time frame. Our data contrast with BPV results from randomized control trials in which drugs are titrated based on a fixed protocol, thus minimizing within-subject and between-subject variability. In reallife clinical practice, the spectrum of patients is unselected and the treatment titration/escalation varies with each patient, with the goal of getting the BP to target. Although we have no data on drug adherence within our study, we have previously published an article on heart rate and mortality in these patients, where we showed >90% of those who were prescribed β-blockers had heart rate <70 per minute. 26 This would suggest that nonadherence to treatment may not be a major factor among the patients who attend clinic regularly and these are patients included in the current analyses. We have not been able to study the role of specific antihypertensive agents; however, we looked at heart rate as a surrogate for β-blockers (presumed to increase BPV) 17, 20 during follow-up to observe whether patients whose variability changed from low to high tracked an opposite change in heart rate because of commencement of β-blocker therapy or other rate-limiting therapy. There was no change in heart rate in the periods Y 2-5 and Y 5-10 of follow-up, which supports our impression that BPV during later years of follow-up is largely dissociated from treatment-induced BPV. Though we have adjusted for all the measured covariates, in an observational study, this is not perfect and it is probable that residual confounding may exist. Finally, the nature of the analysis required us to exclude deaths that occurred during the time frame over which BPV was calculated; further, we also had to exclude individuals who did not have the requisite number of BP measurements within the time frame.
Perspectives
We propose that long-term and ultra long-term visit-to-visit BPV is a prognostic marker that is independent of BP and it probably captures a biological process different from BP regulation. Further clinical implications depend on whether there are interventions that can change long-term visit-to-visit BPV and whether these interventions will result in improvement in outcomes. To elucidate the pathogenic mechanisms underpinning the risk associated with long-term visit-to-visit BPV, larger general population studies are needed. What Is New?
• Long-term blood pressure variability in treated hypertensive subjects is a predictor of mortality independent of long-term average blood pressure (BP) and other known cardiovascular risk factors.
• Sixty percent of treated hypertensive patients show sustained high or low long-term blood pressure variability, which is an independent predictor of mortality.
What Is Relevant?
• Long-term visit-to-visit BP variability is a prognostic marker that is independent of BP and probably captures a different biological process to BP regulation.
Summary
Monitoring BPV in clinical practice may facilitate risk reduction by identifying treated hypertensive individuals at high risk especially those with BP within the normal range.
Supplementary Methods
Other variables
Smoking status was defined as a binary yes/no variable. Alcohol consumption was categorized into two groups; ≤ 5 and ≥ 6 units per week. Estimated glomerular filtration rate (eGFR) was also categorised into two groups; ≤ 60 and > 60 mL/min.
Outcomes
Records held by the General Register Office for Scotland ensured notification of a subject's death (provided death occurred in the UK) along with the primary cause of death according to the International Classification of Diseases, 10th Revision, Version for 2007 (ICD-10), codes. We considered all-cause deaths, cardiovascular deaths (CVD mortality; ICD-10 codes I00-I99), ischemic heart disease deaths (IHD mortality; ICD-10 codes 120-I25), and stroke deaths (stroke mortality; ICD-10 codes I60-I69) in the analysis. Deaths other than due to cardiovascular causes are classified as non-CVD deaths. Mortality data were collected up to April 2011, allowing a maximum of 35 years for participants who had been under follow up for the longest time.
Formulae used for calculation of BPV and time-weighted average BP: 
Coefficient of Variation
Supplementary Results Agreement between BP variability measured during different follow-up time-frames
To measure degree of congruence of BP variability classification between time-frames, Cramer's V statistics and intraclass correlation coefficients were calculated for both SBP and DBP. Cramer's V statistic assumes that the marginal differences in rows are similar to those for columns and that the change from one category to another is equally likely. The intraclass correlation coefficient provides a scalar measure of agreement or concordance between the BPV categories in different time-frames.
In general there was poor agreement between ARV BP quartiles between different time-frames though the association was significant. The correlation was higher between adjacent timeframes but the magnitude of correlation was small (Cramer's V <0·3, ICC <0·32). (Table S2 and Table S3 , respectively) This was similar for both SBP and DBP measures.
Blood pressure variability and mean blood pressure ARV SBP and ARV DBP were moderately correlated with mean BP, CoeffV BP, and mean BP tw at each follow-up time period (p<0·01; Table S4 ). The highest Spearman correlations were observed during Y 2-5 (mean SBP (mean SBP tw ) and ARV SBP = 0·47, mean DBP and ARV DBP = 0·28, mean DBP tw and ARV DBP = 0·27). ARV DBP in general showed lower correlations to mean DBP compared to similar SBP pairs.
ARV DBP and baseline characteristics
Albeit with a few exceptions, the ARV DBP results were similar to ARV SBP . In contrast with ARV SBP , ARV DBP was not associated with sex, and it decreased with age beyond 30 years (p<0·001). Furthermore, among users of alcohol ARV DBP was higher up to five years followup (p<0·001) ( Table S6B ).
Analysis of coefficient of variation and standard deviation of BP and outcomes
Coefficient of variation (CoeffV) was calculated, for each time frame, as an alternative measure of BPV (CoeffV SBP , CoeffV DBP ). The formula is given above. Values were then multiplied by 100 to generate percent coefficient of variation (CoeffV BP %), and finally quartiles determined for each period. Cox proportional hazards models were used to determine the multivariate risk of cause specific mortality for each quartile of CoeffV BP %, with the lowest quartile serving as the referent. Separate analyses were performed for SBP and DBP, and for each follow-up time-frame. The models were adjusted for mean SBP tw and DBP tw , and baseline cardiovascular risk factors including: age, sex, smoking, alcohol consumption, BMI, total cholesterol, prevalent cardiovascular disease (CVD), and eGFR. Furthermore, in analyses of Y 1 and Y 2-5 a variable on year of first visit strata (epochs) was included to adjust the secular trend in mortality and was divided into five categories (first visit 1976 or before, between years 1977-1987, 1988-1997, 1998-2004, 2005 and after). Logminus-log plots were analysed for any suggestion of deviation from the proportional hazards assumption.
Similar analysis was repeated for standard deviation (SD SBP , SD DBP ). CoeffV% and SD of SBP quartiles showed associations nearly similar to ARV but not as consistent. (Table S9 and S11). 
ARV=average real variability, SBP=systolic blood pressure, SD=standard deviation, BMI=body mass index, CKD=chronic kidney disease, CVD=cardiovascular disease, DBP=diastolic blood pressure.
6 Table S2 : Dependency between average real blood pressure variability measurements in quartiles (Cramer's V statistics). Table S3 : Intraclass correlation coefficients (ICC) between average real blood pressure variability in quartiles.
Variables
Year SBP=systolic blood pressure, DBP=diastolic blood pressure, ARV=average real variability, tw =time weighted, CoeffV=coefficient of variation, r=Spearman's correlation coefficient, *p<0.01, †p<0.001. 
